Lynparza on a roll with early breast cancer win

Lynparza (olaparib) partners AstraZeneca (LSE: AZN) and Merck & Co (NYSE: MRK) have reported updated findings from the Phase III OlympiA trial in breast cancer, showing a sustained survival benefit.

The data, presented at the San Antonio Breast Cancer Symposium, confirm Lynparza’s benefit in reducing the risk of death by 28% compared to placebo, with 87.5% of treated patients alive after six years versus 83.2% in the placebo group.

The results, which relate to people with germline BRCA-mutated HER2-negative high-risk early breast cancer, build on the trial's primary results, published in The New England Journal of Medicine.